Third Security Lowers stake in Intrexon Corp (XON)

Intrexon Corp (XON) : Third Security reduced its stake in Intrexon Corp by 0.55% during the most recent quarter end. The investment management company now holds a total of 61,904,943 shares of Intrexon Corp which is valued at $1,750,052,739 after selling 341,454 shares in Intrexon Corp , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Intrexon Corp makes up approximately 80.28% of Third Security’s portfolio.

Other Hedge Funds, Including , B T Capital Management Dba Alpha Capital Management sold out all of its stake in XON during the most recent quarter. The investment firm sold 52,884 shares of XON which is valued $1,495,031.Rpg Investment Advisory boosted its stake in XON in the latest quarter, The investment management firm added 15,900 additional shares and now holds a total of 68,950 shares of Intrexon Corp which is valued at $1,977,486. Intrexon Corp makes up approx 0.50% of Rpg Investment Advisory’s portfolio.Utah Retirement Systems boosted its stake in XON in the latest quarter, The investment management firm added 1,300 additional shares and now holds a total of 10,000 shares of Intrexon Corp which is valued at $283,900. Intrexon Corp makes up approx 0.01% of Utah Retirement Systems’s portfolio.Concert Wealth Management reduced its stake in XON by selling 2,694 shares or 22.88% in the most recent quarter. The Hedge Fund company now holds 9,081 shares of XON which is valued at $230,022. Intrexon Corp makes up approx 0.03% of Concert Wealth Management’s portfolio.

Intrexon Corp closed down -0.19 points or -0.65% at $29.16 with 13,88,926 shares getting traded on Friday. Post opening the session at $29.4, the shares hit an intraday low of $28.75 and an intraday high of $29.45 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Intrexon Corp reported $-0.42 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.28. The company had revenue of $52.50 million for the quarter, compared to analysts expectations of $53.78 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.